Bone Abstracts

Antiresorptives consistently improve bone mass and structural strength in normally- and under-loaded bones, but concerns have been raised regarding potential effects on skeletal adaptation to fatigue loading, including damage accumulation and atypical fractures. We thus inhibited or activated osteoclasts with OPG-Fc or RANKL treatment, respectively, and evaluated bone damage and strength after fatigue in the early and later phases of repair. Adult male mice were treated with R...

see PP355....

In clinical studies, denosumab (DMAb) administration up to 8 years is associated with continued increases in bone mineral density (BMD) and low fracture incidence despite persistently low bone turnover markers and limited iliac crest tetracycline labelling (Papapoulos 2013). We tested the hypothesis that, with persistently low bone remodelling, BMD increases may result from a non-remodelling dependent mechanism to accrue bone matrix. We examined the fluorochrome labelling patt...